Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Ed Ajootian who wrote (953)	7/2/1998 9:49:00 PM
From: bazer	Read Replies (3) \| Respond to of 10280

This is the news that will push Sepracor back up. I don't post much here but if this drug is as good as promised it won't take long to gain market share. I'm confident of this because of what I've witnessed over the years as an RRT. Whenever a new bronchodilator has hit the market with less side affects than the old and at lower dosages it is readily accepted. Been there done that. Please don't worry about managed care because the use of a drug like this is physician driven. If they want it for their patients its going to be ordered and will be used. The only thing that could derail it would be a different drug with superior strength and less side affects and I haven't heard of any in the journals. Bazer